There are 2949 resources available
1289P - Efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Presenter: Alexander Drilon
Session: E-Poster Display
Resources:
Abstract
1290P - Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC)
Presenter: Oliver Gautschi
Session: E-Poster Display
Resources:
Abstract
1291P - Hypersensitivity reactions (HR) to selpercatinib in RET fusion+ non-small cell lung cancer (NSCLC) patients (pts) following immune checkpoint inhibition (CPI)
Presenter: Caroline McCoach
Session: E-Poster Display
Resources:
Abstract
1292P - Exploratory patient-reported outcomes (PROs) among patients with RET-fusion non-small cell lung cancer (NSCLC) in LIBRETTO-001: A phase I/II trial of selpercatinib
Presenter: Anna Minchom
Session: E-Poster Display
Resources:
Abstract
1293P - IMpower150: Updated efficacy analysis in patients with EGFR mutations
Presenter: Martin Reck
Session: E-Poster Display
Resources:
Abstract
1294P - RELAY, erlotinib plus ramucirumab or placebo in untreated EGFR-mutated metastatic NSCLC: Outcomes by EGFR mutation type
Presenter: Kazuhiko Nakagawa
Session: E-Poster Display
Resources:
Abstract
1295P - Osimertinib vs comparator EGFR-TKI as first-line treatment for EGFR mutated (EGFRm) advanced NSCLC: FLAURA China study overall survival (OS)
Presenter: Ying Cheng
Session: E-Poster Display
Resources:
Abstract
1296P - BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Presenter: Stefanie Schalm
Session: E-Poster Display
Resources:
Abstract
1298P - RELAY, ramucirumab plus erlotinib (RAM+ERL) versus placebo plus erlotinib (P+ERL) in untreated EGFR mutated metastatic non-small cell lung cancer (NSCLC): Exposure-response relationship
Presenter: Kazuhiko Nakagawa
Session: E-Poster Display
Resources:
Abstract
1299P - Real-world treatment patterns, clinical outcomes and EGFR/T790M testing practices in patients with EGFRm advanced NSCLC and 1L EGFR TKI therapy: A retrospective multinational study (REFLECT)
Presenter: Alfredo Addeo
Session: E-Poster Display
Resources:
Abstract